United European Gastroenterology Journal最新文献

{"title":"Effectiveness and Safety of Advanced Dual-Targeted Therapy in Refractory Perianal Crohn's Disease.","authors":"Nadia Fathallah, Mario Pagano, Mohamed Amine Haouari, Amélie Barré, Calina Atanasiu, Edouard Chambenois, Isabelle Nion-Larmurier, Stéphane Morisset, Julien Kirchgesner, Vincent de Parades","doi":"10.1002/ueg2.70059","DOIUrl":"10.1002/ueg2.70059","url":null,"abstract":"<p><strong>Introduction: </strong>Perianal Crohn's disease (CD) remains challenging to treat despite the increasing number of advanced therapies. Advanced dual-targeted therapy has emerged as a new treatment option in CD, but no data are available for perianal CD. The aim of this study was to evaluate the effectiveness and safety of advanced dual-targeted therapy for anoperineal fistulas (APFs) in CD patients.</p><p><strong>Materials and methods: </strong>We prospectively included all consecutive patients receiving an advanced dual-targeted therapy for APFs from August 2019 to December 2023 in a single tertiary perianal CD centre. The primary outcome was clinical effectiveness. Secondary outcomes were patients' treatment perception, radiological effectiveness, luminal disease effectiveness, impact on extra-intestinal manifestations, and safety. Factors associated with complete clinical remission of APFs were identified using logistic regression.</p><p><strong>Results: </strong>A total of 33 patients were included. The most frequently used advanced dual-targeted therapy was a combination of infliximab and ustekinumab (75.8%). After a median follow-up of 27.4 months, 48.5% and 97.0% of patients were in complete clinical remission and reported a perceived improvement, respectively. Complete radiological remission was achieved in 24.2% of the patients. A concomitant improvement in luminal intestinal involvement was observed in 46.1% of cases, and in extra-digestive manifestations in 45.8% of cases. Treatment tolerance was considered good or very good in 90.9% of cases. Associated anal ulcers and long-term exposure to antibiotics were associated with a lower likelihood of complete clinical remission for fistulas.</p><p><strong>Conclusion: </strong>These findings suggest that advanced dual-targeted therapy is a valid option with a good safety profile for the treatment of refractory APFs. Larger studies are required to identify the most effective combination.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nurse-Administered Gut-Directed Hypnotherapy for Irritable Bowel Syndrome: A Two-Year Follow-Up Study.","authors":"Jenny Lövdahl, Michaela Blomqvist-Storm, Olafur S Palsson, Gisela Ringström, Hans Törnblom, Magnus Simrén, Inês A Trindade","doi":"10.1002/ueg2.70060","DOIUrl":"https://doi.org/10.1002/ueg2.70060","url":null,"abstract":"<p><strong>Background: </strong>Gut-directed hypnotherapy is effective for irritable bowel syndrome (IBS) and a few studies have reported long-lasting therapeutic effects following intervention. No previous studies have evaluated the long-term effects of nurse-administered hypnotherapy.</p><p><strong>Aims: </strong>We aimed to investigate the long-term effects of nurse-administered gut-directed hypnotherapy for IBS and identify factors associated with symptom improvement. Furthermore, we aimed to compare treatment effects between individual and group hypnotherapy.</p><p><strong>Methods: </strong>A 2-year follow-up study including 289 patients with IBS who had completed a 12-week hypnotherapy program (individually or in groups) was conducted. Data were collected at baseline, and at 6-month-, 1-year- and 2-year follow-ups. Irritable bowel syndrome and extracolonic symptom severity (IBS-SSS), gastrointestinal-specific anxiety (VSI), and anxiety and depressive symptoms (HADS) were assessed. Patients reporting a reduction ≥ 50 points (IBS-SSS) were classified as treatment responders.</p><p><strong>Results: </strong>The 2-year follow-up was completed by 207 patients. The proportion of responders at post-treatment was 64.3%, 62.8% at the 6-month follow-up, 64.7% at the 1-year follow-up, and 61.8% at the 2-year follow-up. The severity of IBS symptoms, extracolonic and psychological symptoms were all reduced post-treatment, and this effect lasted over the 2-year follow-up period (p < 0.001). Younger age, individual hypnotherapy, and severe irritable bowel syndrome symptoms at baseline predicted a better response to treatment (R² = 0.16).</p><p><strong>Conclusions: </strong>Nurse-administered gut-directed hypnotherapy is an effective treatment for IBS with long-lasting symptom improvements. Younger age, severe irritable bowel syndrome symptoms, and individual treatment might be important factors associated with effectiveness (ClinicalTrials.gov study protocol IDs: NCT06167018, NCT03432078).</p><p><strong>Trial registration: </strong>ClinicalTrials.gov study protocol IDs: NCT06167018, NCT03432078.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety.","authors":"Massimo C Fantini, Diego Centonze, Giovanni Giacobazzi, Silvia Benemei, Emanuele Romeo","doi":"10.1002/ueg2.70026","DOIUrl":"https://doi.org/10.1002/ueg2.70026","url":null,"abstract":"<p><p>Ulcerative colitis is a chronic immune-mediated inflammatory disease of the colon that causes considerable morbidity and increases the risk of colorectal cancer. Several targeted therapies have been developed for moderate-to-severe ulcerative colitis, significantly improving its management. Ozanimod and etrasimod, oral small-molecule drugs, are the latest addition. They belong to the class of sphingosine-1-phosphate receptor (S1PR) modulators and are the first members of this class to be granted approval for ulcerative colitis. They act by blocking lymphocyte trafficking from lymph nodes to inflamed tissues without impairing other immune system functions. This narrative review summarizes current knowledge of sphingosine-1-phosphate receptor modulators, focusing on safety. Safety data from the field of multiple sclerosis (MS) will be discussed because the first S1PR modulator to reach the market, fingolimod, was used extensively for relapsing-remitting MS. Indications for the safe use of ozanimod and etrasimod in ulcerative colitis patients will be provided.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Efficacy and Safety of Digital-Single-Operator-Video-Pancreatoscopy Guided Lithotripsy for Pancreatic Duct Stones.","authors":"Claudio C Conrad, Mark Ellrichmann, Michiel Bronswijk, Schalk van der Merwe, Tobias Dertmann, Hadil Layka, Radhika Chavan, Sanjay Rajput, Pieter Jan de Jonge, Peter D Siersema, Marianne Udd, Leena Kylanpaa, Philip Grunert, Gilbert Rahe, Christoph Schramm, Jassin Rashidi-Alavijeh, Marco J Bruno, Torsten Beyna, Christian Gerges","doi":"10.1002/ueg2.70063","DOIUrl":"https://doi.org/10.1002/ueg2.70063","url":null,"abstract":"<p><strong>Introduction: </strong>Ductal decompression has become the main approach for treating patients with symptomatic chronic calcifying pancreatitis and signs of ductal hypertension. Digital single operator video pancreatoscopy (dSOVP) has shown high success rates when compared with more established techniques such as extracorporeal shock wave lithotripsy. However, there is still limited evidence on long-term clinical success and quality of life.</p><p><strong>Methods: </strong>Patients with chronic calcifying pancreatitis who underwent digital single operator video pancreatoscopy guided electrohydraulic lithotripsy (EHL) of pancreatic duct stones with initial technical and clinical success were recruited for this retrospective, multicenter cohort study. Persistence of clinical success (defined as pain reduction > 50% in numerical rating scale [NRS]) as well as postinterventional quality of life (QOL) were retrospectively evaluated by database analysis and with QOL using the Mental and Physical Condition Scores (MCS, PCS).</p><p><strong>Results: </strong>A total of 58 patients were included in the long-term follow-up conducted over 24 months. Significant and sustained pain relief was reported in 70.7% of patients (n = 41) at month 3; this effect persisted until month 24. MCS decreased from 50.36 ± 13.3 at baseline to 49.75 ± 11.1 at month 12 with no statistically significant difference (data available for 42 patients, p = 0.15). Similarly, the PCS showed no significant improvement, remaining constant at 44.9 ± 9.8 at baseline and 44.9 ± 10.8 at month 12 (p = 0.1). The overall adverse event rate was 26% (11 patients), primarily consisting of mild to moderate pancreatitis (n = 9, 22%).</p><p><strong>Conclusions: </strong>Digital single operator video pancreatoscopy guided lithotripsy was shown to be safe and effective in a long-term follow-up regarding pain control but had no significant influence on QOL. Complete stone removal seems to be the key point for long-term clinical success.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcutaneous Auricular Vagal Nerve Stimulation to Treat Chronic Constipation: Another Therapeutic Failure?","authors":"Gabrio Bassotti, Danilo Consalvo","doi":"10.1002/ueg2.70065","DOIUrl":"https://doi.org/10.1002/ueg2.70065","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Nicola Pugliese, Ivan Arcari, Federica Cerini, Rosa Lombardi, Federica Turati, Grazia Pennisi, Matteo Soleri, Simone Rocchetto, Diletta De Deo, Michele Sagasta, Chiara Masetti, Anna Ludovica Fracanzani, Salvatore Petta, Carlo La Vecchia, Mauro Viganò, Alessio Aghemo","doi":"10.1002/ueg2.70055","DOIUrl":"https://doi.org/10.1002/ueg2.70055","url":null,"abstract":"<p><strong>Background and aims: </strong>Weight loss is an effective therapeutic strategy for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to identify factors that predict relevant weight loss, defined as at least 7% of initial body weight, in MASLD outpatients.</p><p><strong>Method: </strong>We retrospectively included all MASLD patients referred to four Italian tertiary centers between January 2019 and December 2021. Patients received lifestyle modification advice according to current guidelines, with reassessment of anthropometric measures after 18-24 months.</p><p><strong>Results: </strong>A total of 897 patients were included. The majority were male (57%) with a mean age of 61.6 ± 13.3 years and a mean baseline body mass index (BMI) of 30.3 ± 4.5 kg/m². Comorbidities included type 2 diabetes (T2D; 36%), arterial hypertension (54.7%) and dyslipidemia (55.2%). Over a median observation period of 21 months, 164 (18.3%) patients achieved relevant weight loss. Multiple adjusted regression analysis identified baseline BMI between 30 and 34.9 kg/m² (odds ratio, OR = 1.95, 95% confidence interval, CI: 1.30-2.95) or ≥ 35 kg/m² (OR = 2.08, 95% CI: 1.21-3.57), use of GLP-1 agonists for T2D (OR 1.85, 95% CI: 1.19-3.80), bilirubin levels ≥ 1.2 mg/dL (OR 2.12, 95% CI: 1.29-3.51) nutritionist support (OR 2.04, 95% CI: 1.12-3.71) and liver stiffness measurement (LSM) ≥ 10 kPa (OR 1.70, 95% CI: 1.07-2.70) as independent predictors of relevant weight loss.</p><p><strong>Conclusions: </strong>Baseline BMI ≥ 30 kg/m², use of GLP-1 agonists, elevated bilirubin levels, support from a nutritionist and LSM ≥ 10 kPa are significant predictors of relevant weight loss in MASLD patients. These findings underscore the importance of personalized interventions in MASLD management.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma POSTN Derived From Bile Proteome Is a Promising Biomarker for Cholangiocarcinoma With Efficacy Comparable and Complementary to CA19.9.","authors":"Lichieh Julie Chu, Chia-Jung Tsai, Chun-Chun Chien, Yung-Chin Hsiao, Jau-Song Yu, Jun-Yi Tsai, Ta-Sen Yeh","doi":"10.1002/ueg2.70054","DOIUrl":"https://doi.org/10.1002/ueg2.70054","url":null,"abstract":"<p><strong>Background: </strong>Cholangiocarcinoma presents a global health challenge due to its increasing incidence and poor prognosis, primarily resulting from delayed diagnosis. There is an urgent need for a reliable biomarker to enhance early detection.</p><p><strong>Materials and methods: </strong>Patients with cholangiocarcinoma were enrolled into three cohorts: a discovery set (n = 6), a verification set (n = 34), and a validation set (n = 146), for seeking potential biomarkers, while patients with gallstones served as controls. Three cholangiocarcinoma transcriptome datasets from the gene expression omnibus (GEO) were analyzed. Techniques employed included liquid chromatography-tandem mass spectrometry (LC-MS/MS), multiple reaction monitoring, and enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Using a discovery set, bile proteome profiling identified 57 upregulated proteins that were either unique to cholangiocarcinoma or exhibited ≥ 2-fold changes compared to controls. The GEO transcriptome datasets yielded 48 upregulated genes consistently expressed in cholangiocarcinoma. POSTN (periostin) emerged as a viable biomarker by intersecting these two omics analyses. In the verification set, bile and plasma POSTN levels in cholangiocarcinoma were 4.7-fold and 2.1-fold higher, respectively, compared to controls. In the validation set, the sensitivity, specificity, and AUC of plasma POSTN for diagnosing cholangiocarcinoma were 78%, 85%, and 0.86, respectively, compared to 67%, 90%, and 0.86 for CA19.9. The combination of plasma POSTN and CA19.9 improved these metrics to 87%, 91%, and 0.94, respectively. Protein interactome analysis demonstrated that POSTN was predominantly connected to structural proteins of extracellular matrix (ECM). Patients with higher plasma POSTN levels exhibited higher expression of transcriptional regulators of epithelia-mesenchymal transition (EMT) and worse overall survival compared with those with lower levels.</p><p><strong>Conclusions: </strong>Plasma POSTN, derived from the bile proteome, demonstrates both comparable and complementary efficacy to CA19.9, emerging as a promising biomarker for diagnosing cholangiocarcinoma. Beyond its diagnostic capability, POSTN's role in extracellular matrix interactions and EMT regulation highlights its prognostic potential.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Case of Mantle Cell Lymphoma With Multiple Rectal Lesions.","authors":"Lumir Kunovsky, Eliska Tvrdikova, Jozef Michalka, Jan Trna","doi":"10.1002/ueg2.12752","DOIUrl":"10.1002/ueg2.12752","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":"831-833"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Impact of COVID-19 on Disorders of Gut-Brain Interaction: Incidence, Symptom Burden, and Psychological Comorbidities.","authors":"Giovanni Marasco, Keren Hod, Luigi Colecchia, Cesare Cremon, Maria Raffaella Barbaro, Giulia Cacciari, Francesca Falangone, Anna Kagramanova, Dmitry Bordin, Vasile Drug, Egidia Miftode, Pietro Fusaroli, Salem Youssef Mohamed, Chiara Ricci, Massimo Bellini, M Masudur Rahman, Luigi Melcarne, Javier Santos, Beatriz Lobo, Serhat Bor, Suna Yapali, Deniz Akyol, Ferdane Pirincci Sapmaz, Yonca Yilmaz Urun, Tugce Eskazan, Altay Celebi, Huseyin Kacmaz, Berat Ebik, Hatice Cilem Binicier, Mehmet Sait Bugdayci, Munkhtsetseg Banzragch Yağcı, Husnu Pullukcu, Berrin Yalınbas Kaya, Ali Tureyen, İbrahim Hatemi, Elif Sitre Koc, Goktug Sirin, Ali Riza Calıskan, Goksel Bengi, Esra Ergun Alıs, Snezana Lukic, Meri Trajkovska, Dan Dumitrascu, Antonello Pietrangelo, Elena Corradini, Magnus Simren, Jessica Sjolund, Navkiran Tornkvist, Uday C Ghoshal, Olga Kolokolnikova, Antonio Colecchia, Jordi Serra, Giovanni Maconi, Roberto De Giorgio, Silvio Danese, Piero Portincasa, Antonio Di Sabatino, Marcello Maggio, Elena Philippou, Yeong Yeh Lee, Daniele Salvi, Alessandro Venturi, Claudio Borghi, Marco Zoli, Paolo Gionchetti, Pierluigi Viale, Vincenzo Stanghellini, Giovanni Barbara","doi":"10.1002/ueg2.70005","DOIUrl":"10.1002/ueg2.70005","url":null,"abstract":"<p><strong>Background: </strong>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the potential exacerbation of gastrointestinal symptoms in patients with disorders of gut-brain interaction (DGBIs). However, the distinct symptom trajectories and psychological burden in patients with post-COVID-19 DGBIs compared with patients with pre-existing irritable bowel syndrome (IBS)/functional dyspepsia (FD) and non-DGBI controls remain poorly understood.</p><p><strong>Objectives: </strong>To examine the long-term gastrointestinal symptom progression and psychological comorbidities in patients with post-COVID-19 DGBI, patients with pre-existing IBS/FD and non-DGBI controls.</p><p><strong>Methods: </strong>This post hoc analysis of a prospective multicenter cohort study reviewed patient charts for demographic data and medical history. Participants completed the Gastrointestinal Symptom Rating Scale at four time points: baseline, 1, 6, and 12 months, and the Hospital Anxiety and Depression Scale at 6 and 12 months. The cohort was divided into three groups: (1) post-COVID-19 DGBIs (2) non-DGBI, and (3) pre-existing IBS/FD, with the post-COVID-19 DGBIs group compared to the latter two control groups.</p><p><strong>Results: </strong>Among 599 eligible patients, 27 (4.5%) were identified as post-COVID-19 DGBI. This group experienced worsening abdominal pain, hunger pain, heartburn, and acid regurgitation, unlike symptom improvement or stability in non-DGBI controls (p < 0.001 for all symptoms, except hunger pain, p = 0.001). While patients with pre-existing IBS/FD improved in most gastrointestinal symptoms but worsened in constipation and incomplete evacuation, patients with post-COVID-19 DGBI exhibited consistent symptom deterioration across multiple gastrointestinal domains. Anxiety and depression remained unchanged in patients with post-COVID-19 DGBI, contrasting with significant reductions in controls (non-DGBI: p = 0.003 and p = 0.057; pre-existing IBS/FD: p = 0.019 and p = 0.007, respectively).</p><p><strong>Conclusions: </strong>COVID-19 infection is associated with the development of newly diagnosed DGBIs and distinct symptom trajectories when compared with patients with pre-existing IBS/FD. Patients with post-COVID-19 DGBI experience progressive gastrointestinal symptom deterioration and persistent psychological distress, underscoring the need for tailored management strategies for this unique subgroup.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":"798-818"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are Education, Socioeconomic Status, and Household Size Dependent Variables Influencing the Developmental Origins of Inflammatory Bowel Disease?","authors":"Richard Kellermayer","doi":"10.1002/ueg2.70018","DOIUrl":"10.1002/ueg2.70018","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":"843-844"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}